CELLECTISAct. Nom. Aktie [WKN DE: A0MKPR / ISIN: FR0010425595]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu CELLECTISAct. Nom.

03.12.15		Cellectis Announces Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier (Businesswire)
30.11.15		Cellectis Announces Presentations at Upcoming Conferences (Businesswire)
19.11.15		Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies (Businesswire)
16.11.15		Cellectis Reports Third Quarter and First Nine Months 2015 Financial Results (Businesswire)
05.11.15		Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Product Candidates during the Upcoming ASH Annual Meeting (Businesswire)
05.11.15		Cellectis: UCART19: First in Man Proof of Concept to Be Presented at 2015 ASH Annual Meeting (Businesswire)
28.10.15		Successful GMP Production Process for UCART19 (Businesswire)
09.09.15		Cellectis Announces Presentations at Upcoming Conferences (Businesswire)
08.09.15		Cellectis Reports Second Quarter and First Half Year 2015 Financial Results (Businesswire)
03.09.15		MD Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy (Businesswire)
26.08.15		Cellectis to Present Data on its CAR T-Cell Immunotherapy Programs During Upcoming Conferences (Businesswire)
16.07.15		Cellectis Announces Publication of an Article in Cancer Research on Allogeneic CAR T-cell Immunotherapies (Businesswire)
08.07.15		Cellectis Reaches Milestone in Servier Collaboration (Businesswire)
10.06.15		Cellectis Announces Promising Study on Next Generation Engineered Allogeneic CAR T-cells (Businesswire)
09.06.15		S&W Seed Company and Calyxt, Inc. Announce Alfalfa Seed Collaboration (Businesswire)
09.06.15		Cellectis Reports First Quarter 2015 Financial Results (Businesswire)
05.06.15		Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Programs at the European Hematology Association Annual Meeting (Businesswire)
02.06.15		Weill Cornell Medical College and Cellectis Announce Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia (Businesswire)
20.05.15		Cellectis SA Combined General Shareholders’ Meeting of May 18, 2015 (Businesswire)
08.05.15		Cellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting (Businesswire)
05.05.15		Cellectis S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary (Businesswire)
16.04.15		Cellectis Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in Plants (Businesswire)
15.04.15		Cellectis Plant Sciences, Inc. Publishes a Study Demonstrating Reduced Acrylamide in Fried Potatoes (Businesswire)
10.04.15		Cellectis Announces Presentations at Upcoming Conferences (Businesswire)
09.04.15		Cellectis Opens Labs and Offices in Manhattan, New York (Businesswire)
25.03.15		Cellectis Prices Initial Public Offering of American Depositary Shares (Businesswire)
04.03.15		Cellectis: 2014 Financial Results (Businesswire)
17.02.15		Cellectis SA Shareholders General Meeting of February 16, 2015 (Businesswire)
13.01.15		Cellectis and Ohio State University, Through the Ohio State Innovation Foundation, Enter Into Licensing Agreement for Chimeric Antigen Receptor Technology Targeting Multiple Myeloma (Businesswire)
08.01.15		Cellectis Plans to Conduct Registered Initial Public Offering in the U.S. (Businesswire)
06.01.15		Cellectis Announces the Issuance by the USPTO of a Patent Covering a Seminal Nuclease-Based "gene editing” Method (Businesswire)
18.12.14		Cellectis Plant Sciences and Two Blades Foundation Announce the Execution of a Cross-License Agreement on TAL Effector Nuclease Technologies (Businesswire)
24.11.14		Cellectis Announces Upcoming Presentations at the 56th Annual Meeting of the American Society of Hematology (ASH) (Businesswire)
12.11.14		Cellectis Received Proceeds of €13 Million Through the Exercise of Warrants (Businesswire)
04.11.14		Cellectis: TALENTM Technology: Grant of EP 2 510 096 by the European Patent Office (Businesswire)
30.10.14		Cellectis: Event Report: Individual Shareholders’ Meeting Held on October 23, 2014 (Businesswire)
30.09.14		Cellectis: First-Half 2014 Financial Results (Businesswire)
29.09.14		Cellectis Plant Sciences Launches Its New Website (Businesswire)
23.09.14		Cellectis : Individual Shareholder Meeting (Businesswire)
16.09.14		Event report: Cellectis R&D/ Analyst Day (Businesswire)
04.09.14		Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc. (Businesswire)
02.09.14		Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology (Businesswire)
31.07.14		Pfizer’s Stake in Cellectis’ Capital is Welcomed by Its Shareholders (Businesswire)
29.07.14		Cellectis Sells Its Swedish Subsidiary, Cellectis AB, to the Japanese Company Takara Bio Inc. (Businesswire)
30.06.14		Cellectis SA Combined General Shareholders’ Meeting of June 27, 2014 (Businesswire)
25.06.14		Cellectis R&D / Analyst Day (Businesswire)
23.06.14		Cellectis’ UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA (Businesswire)
19.06.14		Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014 (Businesswire)
18.06.14		Pfizer and Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration (Businesswire)
10.06.14		Cellectis to Present New Data Update on Its Allogeneic CAR T Cell Therapeutics at the 19th Congress of the European Hematology Association (EHA) (Businesswire)

Erste Seite Zurück | ... | 2 | 3 | 4 | 5 | Weiter

Newssuche

Meistgelesene Nachrichten

Mit Ripple zum Millionär aufsteigen? So könnte es klappen!

Diese Aktien empfehlen Experten zu kaufen

Bitcoinkurs übersteigt 100.000-Dollar-Schwelle und gibt dann Gewinn wieder komplett ab

Krypto top, Gold flop: Aus diesen Gründen setzt Mark Cuban bei Wirtschaftsschwäche auf Bitcoin

Goldpreis: Ruhe vor dem nächsten Sturm?

DAX Rises Nearly 1% On Encouraging Earnings, Economic Data

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	10.02.2025 13:31
Kaufwert:	EUR
	Hinzufügen Speichern